抗血小板药物的研究进展
作者：沈琳;林钟香;
Author：
收稿日期： 年卷（期）页码：2006,(03):-312-314
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：血小板;花生四烯酸;环核苷酸;激动剂;受体药物;血小板聚集
Key words：
基金项目：
中文摘要
对抗血小板类药物的分类、机理、发展现状等进行综述。
参考文献
[1]郭新胜,施海明.不同剂量阿司匹林对冠心病患者血小板聚集功能的影响[J].现代诊断与治疗,2002,13(2):105-106.
[2]Kulbertus H.Aspirin:recent advances in cardiovascular prevention[J].Rev Med Liege,2004,59(12):695-703.
[3]Shimazawa M,Takiguchi Y,Umemura K,et al.Antithrombotic effectsof KBT-3022,a novel antiplatelet agent,in an arterial thrombosismodel in the guinea-pig[J].Drug Dev Res,1997,40(3):217-222.
[4]Sueda S,Kohno H,Inoue K,et al.Intracoronary administration of athromboxane A2synthase inhibitor relieves acetylcholine-inducedcoronary spasm[J].Circulation,2002,66(9):826-830.
[5]Y Kimura.Selective typeⅢphosphodiesterase inhibitor as an an-tithrombotic agent[J].Nippon Yakurigaku Zasshi,1995,106(3):205-216.
[6]Inone T,Uchida T,Sakuma M,et al.Cilostazol inhibits leukocyte inte-grin Mac-1,leading to a potential reduction in restenosis after coro-nary stent implantation[J].J Am Coll Cardiol,2004,44(7):1408-1414.
[7]Petrone M,Silverstein M,Petitt R,et al.The cardiovascular effects ofanagrelide HCI in thrombocythemic subjects with and without priormedical history of cardiovascular disease[J].Clin Pharmacol Ther,1995,57(2):40-42.
[8]穆莉,华维一,彭司勋.FUROXAN类化合物作为NO供体在心血管作用方面的研究[J].药学进展,1997,21(1):14-19.
[9]Takeuchi K,Ukawa H,Konaka A,et al.Effect of nitric oxide-releas-ing aspirin derivative on gastric functional and ulecrogenic responses inrats:comparison with plain aspirin[J].J Pharmacol Exp Ther,1998,286(1):115-121.
[10]Quinn MJ,Fitzgerald DJ.Ticlopidine and clopidogrel[J].Circulation,1999,100:1667-1672.
[11]Cavusoglu E,Cheng J,Bhatt R,et al.Clopidogrel in the managementof ischemic heart disease[J].Heart Dis,2003,5:144-152.
[12]Caprie Steering Committee.A randomised,blinded,trial of clopidogrelversus aspirin in patients at risk of ischemic events(CAPRIE)[J].Lancet,1996,348:1329-1339.
[13]Salim Yusuf,D Phil.Effects of clopidogrel in addition to aspirin in pa-tients with acute coronary syndromes without ST-segment elevation[J].N Engl Med,2001,345:494-502.
[14]Steinhubl SR,Berger PB,Mann JT,et al.Early and sustained dual an-tiplatelet therapy following percutaneous coronary intervention[J].Ja-ma,2002,288:2411-2420.
[15]Sabatine MS,MPH.,Cannon CP,et al.Addition of clopidogrel to as-pirin and fibrinolytic therapy for myocardial infarction with ST-seg-ment elevation[J].N Engl Med,2005,352:1179-1189.
[16]Delrio M,Sunkel C,Larcher F,et al.Antiproliferative effects of PCA-4230,a new antithrombotic drug in vascular smooth muscle cells[J].Br J Pharmacol,1997,120(7):1360-1366.
[17]Wolfram RM,Kritz H,Oguogho A,et al.Antiplatelet activity of semo-tiadil fumarate[J].Thromb Res,2002,106(4-5):187-190.
[18]Doggrell SA.Sarpogrelate:cardiovascular and renal clinical potential[J].Expert Opin Investig Drugs,2004,13(7):865-874.
[19]Kurose I,Argenbright LW,Wolf R,et al.Ischemia/reperfusion-in-duced microvascular dysfuntion:role of oxidants and lipid mediators[J].Am J Physiol,1997,272:2976-2982.
[20]Honisko ME,Fink JM,Militello MA,et al.Compatibility of argatrobanwith selected cardiovascular agents[J].Am J Health Syst Pharm,2004,61:2415-2418.
[21]许天林,华维一,倪沛洲.非肽类纤维蛋白原受体拮抗剂的研究进展[J].药学进展,1998,22(1):21-27.
[22]Foster RH,Wiseman LR.Abciximab,an updated review of its use inischaemic heart disease[J].Drugs,1998,56(4):629-665.
[23]The EPILOG Investigators.Platelet glycoproteinⅡb/Ⅲa receptorblockade and low-dose heparin during percutaneous coronary revas-cularization[J].N Engl J Med,1997,336:1689-1696.
[24]Mcclellan KJ,Goa KL.Tirofiban,a review of its use in acute coronarysyndromes[J].Drugs,1998,56(6):1067-1080.
[25]The Restore Investigators.Effects of platelet glycoproteinⅡb/Ⅲablockade with tirofiban on adverse cardiac events in patients with un-stable angina or acute myocardial infarction undergoing coronary angio-plasty[J].Circulation,1997,96:1445-1453.
[26]Goa KJ,Noble S.Eptifibatide,a review of its use in patients with acutecoronary syndromes and/or undergoing percutaneous coronary interven-tion[J].Drugs,1999,57(3):439-462.
[27]Randomised placebo-controlled trial of effect of eptifibatide on com-plications of percutaneous coronary intervention:IMPACTⅡ.Integrilinto minimize platelet aggregation and coronary thrombosis-Ⅱ[J].Lancet,1997,349:1422-1428.
[28]International,randomized,controlled trial of lamifiban(a platelet gly-coproteinⅡb/Ⅲa inhibitor),heparin,or both in unstable angina[J].Circulation,1998,97:2386-2395.
[29]William W,Patrick S,Merrill K,et al.Long-term treatment with aplatelet glycoprotein-receptor antagonist after percutaneous coronaryrevascularization[J].N Engl J Med,2000,342:1316-1324.
[30]Malini PL,Strocchi E,Zanardi M,et al.Thromboxane antagonism andcough induced by angiotensin-converting-enzyme inhibitor[J].Lancet,1997,350(9070):15-18.
[31]Suh DY,Kang YH,Han BH.Salicylate 1evels in rat stomach tissuesafter administration of aspalatone and acetylsalicylic acid in relation totheir,ulcerogenicity[J].Arzneim-Forsch/Drug Res,1997,47(7):826-828.
【关闭】
